Skip to main content
Full access
Articles
Published Online: 19 August 2021

Telehealth Adoption by Mental Health and Substance Use Disorder Treatment Facilities in the COVID-19 Pandemic

Abstract

Objective:

The study examined temporal and geographic trends in telehealth availability at U.S. behavioral health treatment facilities and risk factors for not offering telehealth.

Methods:

Longitudinal data on 15,691 outpatient behavioral health treatment facilities were extracted daily from the Substance Abuse and Mental Health Services Administration’s Behavioral Health Treatment Services Locator between January 20, 2020, and January 20, 2021. Facilities operated by the Department of Veterans Affairs were excluded. Bivariate analyses were used to assess trends in telehealth availability in 2020 and 2021. Multivariable regression analysis was used to examine facility- and county-level characteristics associated with telehealth availability in 2021.

Results:

Telehealth availability increased by 77% from 2020 to 2021 for mental health treatment facilities and by 143% for substance use disorder treatment facilities. By January 2021, 68% of outpatient mental health facilities and 57% of substance use disorder treatment facilities in the sample were offering telehealth. Mental health and substance use disorder treatment facilities that did not accept Medicaid as a form of payment were less likely to offer telehealth in 2021, compared with facilities that accepted Medicaid. Mental health and substance use disorder treatment facilities that accepted private insurance were more likely to offer telehealth in 2021, compared with facilities that did not accept private insurance.

Conclusions:

Although 2020 saw a dramatic increase in telehealth availability at behavioral health treatment facilities, 32% of mental health treatment facilities and 43% of substance use disorder treatment facilities did not offer telehealth in January 2021, nearly 1 year into the pandemic.

HIGHLIGHTS

From January 2020 to January 2021, telehealth service availability increased by approximately 77% for outpatient mental health treatment facilities and by 143% for substance use disorder treatment facilities.
By January 2021, 68% of outpatient mental health facilities and 57% of substance use disorder treatment facilities were offering telehealth.
Facilities not accepting Medicaid or private insurance payment were less likely than those accepting these forms of payment to offer telehealth as of January 2021.
The COVID-19 pandemic has created an unprecedented need for the rapid adoption of telehealth services (1). Recommendations from the Centers for Disease Control and Prevention are to limit in-person, nonemergent medical consultations as a way to ensure social distancing and reduce viral spread (2). At the same time, depression, psychological distress, social isolation, and loneliness have markedly increased throughout the United States (3, 4), and there has been a spike in substance use (4) as well as in the number of drug overdose deaths (5). Experts predict escalating strain on the U.S. behavioral health care system as more individuals seek services (613).
Substantial evidence indicates that telehealth services for mental health conditions can be equivalent to in-person care in terms of symptom improvement and client satisfaction (14, 15), although more research is needed to examine outcomes for patients with substance use disorders who receive telehealth services (16, 17). Thus far, professionals, such as psychiatrists, have reported that the recent transition to telehealth has been smoother than expected (18) and that it has reduced the no-show rate (19). Physicians prescribing buprenorphine for opioid use disorder have reported that telehealth has increased access to care for their patients (20, 21). National claims data have shown dramatic increases in telehealth for mental health conditions among those ages 13–22 (22).
Temporary federal policies have facilitated the rapid adoption of telehealth. For example, the Food and Drug Administration has eased rules pertaining to pharmacy dispensing of psychotropic medicines (23). Buprenorphine-waivered prescribers can now initiate buprenorphine treatment remotely—something that previously had required an in-person visit (24). Separately, the Department of Health and Human Services has permitted health providers to utilize videoconferencing platforms that are not in compliance with Health Insurance Portability and Accountability Act rules, as long as they are acting in good faith (25). Many of these policies were designed to last only through the COVID-19 pandemic.
Despite the rapid shift to support telehealth in the health care policy landscape, no national longitudinal studies have examined changes in the availability of telehealth services for behavioral health conditions over the course of the COVID-19 pandemic. To fill the gap, we utilized a national panel data set of mental health and substance use disorder treatment facilities—updated daily—to quantify changes in their offering of telehealth services between January 20, 2020, and January 20, 2021. Furthermore, we examined facility- and county-level characteristics of treatment facilities to identify key risk factors for not adopting telehealth as of 2021.

Methods

The Substance Abuse and Mental Health Services Administration (SAMHSA) collects data from nearly all mental health and substance use disorder treatment facilities in the United States by using the National Mental Health Services Survey (N-MHSS) and National Survey of Substance Abuse Treatment Services (N-SSATS). SAMHSA’s Behavioral Health Treatment Services Locator reports responses from the facilities that have agreed to be listed. The locator is updated continuously with information such as facility name, address, telephone number, and services offered (26). N-SSATS facilities were asked, “Which of the following clinical/therapeutic approaches listed below are used frequently at this facility?” One possible answer was “Telemedicine/telehealth therapy (including Internet, Web, mobile, and desktop programs).” For N-MHSS, the same response was possible; however, the question was worded slightly differently: “Which of these mental health treatment approaches are offered at this facility, at this location?” Facilities that marked a checkmark for this option were defined as offering telehealth.
The data set utilized for this study, the Mental health and Addiction Treatment Tracking Repository, draws daily updates from SAMHSA (27). The data were collected in 2020 and 2021. We excluded facilities that are part of the U.S. Department of Veterans Affairs system, given that they have a unique telehealth system that differs from those of civilian providers and that has existed since before the COVID-19 pandemic. We also restricted our analysis to outpatient treatment facilities, given that in-person visits to these facilities have been reduced in response to the physical distancing precautions required to combat the spread of COVID-19 (28).
We identified outpatient facilities in both the N-MHSS and N-SSATS on the basis of their response to two different questions. In the N-MHSS, the question is as follows: “Mental health treatment is provided in which of the following service settings at this facility, at this location?” A possible response is “outpatient.” In the N-SSATS the question is as follows: “Does this facility offer OUTPATIENT substance abuse services at this location, that is, the location listed on the front cover?” Facilities responding “yes” were classified as an outpatient facility. Our sample included 15,691 outpatient behavioral health treatment facilities—6,601 outpatient mental health and 9,090 outpatient substance use disorder treatment facilities.
We calculated the number and percentage of outpatient mental health and substance use disorder treatment facilities that offered telehealth on January 20, 2020, and January 20, 2021.
We included measures of facility- and county-level characteristics. The facility-level characteristics were from responses to the N-MHSS and N-SSATS within the Behavioral Health Treatment Services Locator, including the service setting of the treatment facility (outpatient only versus inpatient and outpatient), whether the treatment facility accepts Medicaid as a form of payment, whether the treatment facility accepts private insurance as a form of payment, whether the facility provides care for adults only, and the ownership of the facility (public, private not for profit, and private for profit).
County-level characteristics included several features by which we expected that health care service availability may differ on the basis of evidence from the existing literature (2931). Specifically, they included number of COVID-19 cases per 10,000 population from USAFacts (32), urbanicity (33), the share of the county population that speaks only English in the household from the American Community Survey (ACS) (34), the share of the county population without broadband Internet from the Federal Communications Commission (35), the percentage of the population below the federal poverty level from the ACS, the percentage of the population that is black non-Hispanic from the ACS, the percentage of the population that is white non-Hispanic from the ACS, and finally the percentage of the population that is Hispanic from the ACS.
We calculated changes in the number and percentage of the two types of treatment facilities that offered telehealth between January 20, 2020, and January 20, 2021. As a subsequent step, we stratified these estimates according to facility- and county-level characteristics, as described above.
To identify risk factors for facilities not offering telehealth care on January 20, 2021, we executed multivariable mixed-effects linear probability regression analysis. In addition to the facility- and county-level variables as described above, the models also included state fixed effects. Standard errors were clustered at the state level.
Finally, to aid interpretation of these findings, we generated marginal means from the regression models (36). This provides predicted probabilities of not offering telehealth services by January 2021, which can help identify risk factors for not offering telehealth in 2021. All analyses were executed with Stata, version 16.0 (37). The study was deemed exempt by the RAND Corporation’s Human Subjects Protection Committee. All analyses were done in 2021.

Results

As of January 2020, only 33% (N=5,113) of the 15,691 outpatient behavioral health treatment facilities offered telehealth: 42% (N=2,791) of the 6,601 mental health treatment facilities and 26% (N=2,322) of the 9,090 substance use disorder treatment facilities. By January 2021, the percentage of outpatient behavioral health treatment facilities offering telehealth rose to 61% (N=9,639) overall, with 68% (N=4,460) among mental health facilities and 57% (N=5,179) among substance use disorder treatment facilities.
Table 1 summarizes these increases for outpatient mental health and substance use disorder treatment facilities, according to facility- and county-level characteristics. Although the level of telehealth availability between 2020 and 2021 increased substantially for each census region, the increase was not even across regions. The largest increase in the percentage of mental health and substance use disorder treatment facilities offering telehealth occurred in the Northeast (205% and 246% increase, respectively). The magnitude of increase—for almost all characteristics—was higher for substance use disorder treatment facilities than for mental health treatment facilities. For outpatient mental health treatment facilities, percentage changes in nonmetropolitan counties (26%) were smaller than for substance use disorder treatment facilities (79%). For outpatient substance use disorder facilities, higher percentage changes occurred in counties with lower percentages of English-only speaking households (lowest quartile, 147%). For both types of facility, we also found that as the percentage of individuals in poverty in a county increased, so did the availability of telehealth.
TABLE 1. Outpatient mental health treatment facilities and substance use disorder treatment facilities offering telehealth in January 2020 and January 2021a
 Mental health treatment facilities (N=6,601)Substance use disorder treatment facilities (N=9,090)
 20202021Increase20202021Increase
CharacteristicN%N%(%)N%N%(%)
Region
 Midwest72440.81,21868.668.262826.21,35956.6116.4
 Northeast24817.875654.2204.827416.994858.3246.0
 South1,06656.31,38573.129.983930.61,54456.484.0
 West75349.01,10171.746.258125.01,32857.1128.6
Medicaid accepted as payment          
 No12230.720052.463.943818.494543.6115.8
 Yes2,66943.04,26068.559.61,88428.14,23461.2124.7
Private insurance accepted as payment          
 No27330.049557.081.334515.983740.8142.6
 Yes2,51844.33,96569.257.51,97728.64,34261.7119.6
Ownership          
 Government owned53853.373271.836.15128.510558.3105.9
 Private for profit45136.280064.377.489623.32,00852.0124.1
 Private not for profit1,80241.52,92767.562.41,22527.42,72160.9122.1
Urbanicity          
 Metropolitan1,51733.32,85362.688.11,45922.33,62155.5148.2
 Not metropolitan1,26462.71,59479.026.184734.01,51861.079.2
% of households speaking English only (quartile)          
 Lowest1,32432.22,05762.855.41,09022.12,69354.7147.1
 Second73055.91,26470.773.260626.51,32457.9118.5
 Third44860.067272.350.034729.871561.4100.6
 Highest28966.146776.961.627939.144762.660.2
% of households below the federal poverty level (quartile)          
 Lowest65835.61,17763.778.958822.21,47155.4150.2
 Second74440.31,25868.269.164126.71,42859.4122.8
 Third86645.31,32469.252.967924.41,53655.3126.2
 Highest52252.570070.434.141233.174159.579.9
a
Data are from January 20, 2020, and January 20, 2021, in the Behavioral Health Treatment Service Locator. The sample was restricted to outpatient facilities that appeared in the locator on both dates. Facilities run by the U.S. Department of Veterans Affairs were excluded.
Uptake of telehealth services increased in many areas of the country. (Two U.S. maps showing the distribution of telehealth coverage among outpatient mental health treatment facilities at the county level on January 20, 2020, and on January 20, 2021, are included in an online supplement to this article.) The shifting color gradient indicates counties that saw increases of facilities offering telehealth. A total of 246 counties, with a combined population of 23,117,451, that did not have a mental health treatment facility that offered telehealth in 2020 gained at least one that did so in 2021. Nevertheless, as of January 2021, a large percentage of counties (43% of all counties), with a total population of 35,800,015 individuals (11% of the total population), still lacked any mental health treatment facilities offering telehealth.
Adoption of telehealth services by substance use disorder treatment facilities increased across the country, especially in the Midwest and South (see second set of maps in online supplement). A total of 475 counties, with a combined population of 37,992,885, that did not have a substance use disorder treatment facility that offered telehealth in 2020 gained at least one that did so in 2021. Nevertheless, as of January 2021, a large percentage of counties (49% of all counties), with a total population of 36,068,677 individuals (11% of the total population), still lacked any substance use disorder treatment facilities offering telehealth.
Table 2 presents the predicted probabilities of not offering telehealth in 2021 by facility- and county-level characteristics. We report some of the results with statistically significant differences below. The likelihood of not offering telehealth in 2021 differed by region. Compared with mental health facilities in the Northeast (predicted probability of not offering telehealth=0.460, 95% confidence interval [CI]=0.419–0.500), facilities in the three other census regions were all more likely to offer telehealth in 2021: West, predicted probability=0.257, 95% CI=0.218–0.296; Midwest, predicted probability=0.308, 95% CI=0.254–0.363; and South, predicted probability=0.277, 95% CI=0.236–0.318. The difference between the Northeast and the other regions was significant (p<0.001). In contrast, substance use disorder treatment facilities in the Midwest were less likely to offer telehealth in 2021 (predicted probability=0.460, 95% CI=0.412–0.508), compared with such facilities in the South (predicted probability=0.400, 95% CI=0.376–0.425). The difference was significant (p=0.028).
TABLE 2. Regression-adjusted probabilities of mental health and substance use disorder treatment facilities not offering telehealth in 2021a
 Mental health treatment facilitySubstance use disorder treatment facility
 Predicted Predicted 
 probability of probability of 
 not offering not offering 
Characteristictelehealth (%)95% CI (%)telehealth (%)95% CI (%)
Region
 Midwest.308.254–.363.460.412–.508
 Northeast.460.419–.500.451.400–.503
 South.277.236–.318.400.376–.425
 West.257.218–.296.413.357–.469
Medicaid accepted as payment
 No.432.368–.500.506.460–.552
 Yes.312.291–.335.405.379–.430
Private insurance accepted as payment
 No.409.346–.472.549.509–.590
 Yes.306.283–.329.394.370–.418
Ownership
 Government owned.312.259–.366.450.360–.540
 Private for profit.337.291–.382.451.418–.484
 Private not for profit.316.291–.342.410.377–.443
Urbanicity
 Metropolitan.342.315–.369.423.402–.445
 Not metropolitan.269.233–.304.443.406–.480
% of households speaking English only (quartile)
 Lowest.338.304–.372.426.397–.455
 Second.288.255–.321.428.395–.461
 Third.319.267–.371.424.385–.464
 Highest.314.267–.361.455.404–.507
% of households below the federal poverty level (quartile)
 Lowest.329.295–.363.435.409–.462
 Second.315.285–.345.414.387–.441
 Third.314.287–.341.443.409–.478
 Highest.321.275–.366.410.370–.449
a
Additional variables adjusted for in the analysis included COVID-19 prevalence rate per 10,000 population, racial mix of the county, percentage of the county without broadband, whether the facility was only an outpatient facility, whether the facility accepted only adults as patients, and state fixed effects. Standard errors were clustered at the state level.
Mental health treatment facilities that did not accept Medicaid as a form of payment were more likely to not offer telehealth in 2021 (predicted probability of not offering telehealth=0.432, 95% CI=0.368–0.500), compared with facilities that accepted Medicaid (predicted probability=0.312, 95% CI=0.291–0.335). The difference was statistically significant (p<0.001). We also found that mental health treatment facilities that did not accept private insurance as payment had a higher probability of not offering telehealth in 2021 (predicted probability=0.409, 95% CI=0.346–0.472), compared with those that accepted private insurance (predicted probability=0.306, 95% CI=0.283–0.329). The difference was statistically significant (p=0.002). We found similar results for substance use disorder treatment facilities that differed only slightly in their magnitude but that were also significant (p<0.001).
Mental health treatment facilities in metropolitan areas had a higher probability of not offering telehealth in 2021 (predicted probability=0.342, 95% CI=0.315–0.369), compared with facilities in nonmetropolitan areas (predicted probability=0.269, 95% CI=0.233–0.304). The difference was statistically significant (p=0.001). For substance use disorder treatment facilities, we did not find a statistically significant difference in the likelihood of not offering telehealth in 2021 by urbanicity.
No significant differences were noted for either mental health or substance use disorder treatment facilities on the basis of a facility’s ownership or the county-level measures of percentage of households speaking only English and the percentage of the population below the federal poverty level.

Discussion

In this longitudinal analysis of 15,691 outpatient mental health and substance use disorder treatment facilities throughout the United States, we found that telehealth service availability among mental health treatment facilities increased by approximately 77% from January 2020 to January 2021. The increase over the same period was 143% among substance use disorder treatment facilities. We also found differential increases in telehealth adoption across regions. Although facilities in the Northeast experienced the largest increase in telehealth adoption, the region still lagged behind others in terms of telehealth availability per population, especially among outpatient mental health treatment facilities. We also found that outpatient mental health treatment facilities in metropolitan areas were less likely to offer telehealth in 2021, compared with facilities in nonmetropolitan areas. We suspect that a potential cause of the differences in telehealth adoption geographically could be attributable to disproportionate workforce disruptions and existing workforce availability issues. A survey conducted by the National Council for Behavioral Health in April 2020 found that almost half of responding behavioral health organizations throughout the country reported furloughing or discharging employees as a result of COVID-19 (38).
To a large extent, the rapid adoption of telehealth at outpatient mental health and substance use disorder treatment facilities demonstrates the responsiveness of the U.S. health systems to accommodate the constraints introduced by the COVID-19 pandemic. Several case studies have delineated health systems’ efforts to expand telehealth services across the nation during the pandemic (18, 39). For facilities that successfully achieved the transition to telehealth, questions remain about whether and to what extent federal and state governments will maintain policies that support telehealth for behavioral health services (13, 40, 41). Recently, the Centers for Medicare and Medicaid Services announced that Medicare will continue reimbursement codes for telehealth even after the pandemic has been controlled (42). It will be interesting for future studies to examine whether such policies will help maintain or further expand the current telehealth coverage, given our finding that 32% of mental health treatment facilities and 43% of substance use disorder treatment facilities in our sample still did not offer telehealth services in January 2021, nearly 1 year into the pandemic.
We found several significant risk factors that predicted a lack of uptake in telehealth services in 2021, including forms of payment accepted. For both mental health and substance use disorder treatment facilities, not accepting Medicaid was a predictor of not offering telehealth in 2021. One potential explanation for this is that Medicaid predominantly serves low-income, high-needs individuals who may contend with transportation and other barriers to care (43, 44). As such, facilities accepting Medicaid payment may have had a stronger motivation to increase telehealth services. Historically, changes in Medicaid reimbursement have led to changes in telehealth adoption (45). Among substance use disorder treatment facilities, not accepting private insurance payment was a significant predictor of not offering telehealth in 2021. Again, changes in reimbursement could be responsible for offering telehealth by facilities that accept private insurance as payment. For example, 17 states required reimbursement parity for telehealth and in-person services for non–COVID-19 patients (46). Further research is needed to track changes in federal- and state-level policies regarding private insurance coverage of telehealth and to assess how the changes affect telehealth adoption by behavioral health facilities.
This study had several limitations. First, not all outpatient mental health and substance use disorder treatment facilities are in SAMHSA’s Behavioral Health Treatment Services Locator database. Although the vast majority of facilities choose to be listed in the database, it remains unclear what percentage of all facilities decline to be included in it. Second, the locator data do not contain information on treatment capacity or quality, and thus we were not able to determine how many patients could be treated virtually by the facilities that offered telehealth or to assess the quality of care. Third, the Behavioral Health Treatment Services Locator data do not differentiate between telehealth provided by telephone or by video.
Looking forward, outpatient mental health and substance use disorder treatment facilities may consider the long-term implications of maintaining telehealth operations, even if only as part of a broader portfolio of in-person and community-based services. Several studies have indicated reductions in no-show rates for telehealth visits, compared with in-person visits (47, 48); an anticipated potential reduction in overhead for physical infrastructure (49); and new costs necessary to convert providers’ personal spaces (50). From an analytic perspective, our results also underscore the relevance of SAMHSA’s Behavioral Health Treatment Services Locator for regularly tracking service availability at the facility level across the nation. Prior studies have utilized this information cross-sectionally (2931, 5156). Future research may use it to monitor changes in telehealth availability among facilities as the pandemic evolves.

Conclusions

During the COVID-19 pandemic, the percentage of outpatient mental health and substance use disorder treatment facilities offering telehealth has grown dramatically. However, our analyses also indicated that considerable proportions of mental health and substance use disorder treatment facilities still did not offer telehealth as of January 2021, and we identified significant factors associated with this finding. If policy makers wish to increase the number and percentage of behavioral health facilities that provide telehealth, they should consider collecting additional information about why facilities did not institute telehealth during the COVID-19 pandemic. Separately, more work needs to be undertaken to ascertain how increased telehealth availability affects behavioral health care utilization and quality.

Acknowledgments

The authors thank Matthew Cefalu, Ph.D., for providing insight on the analytic approach.

Footnote

The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or decision to submit the manuscript.

Supplementary Material

File (appi.ps.202100191.ds001.docx)

References

1.
What is telehealth? NEJM Catalyst (Epub Feb 1, 2018). https://catalyst.nejm.org/doi/full/10.1056/CAT.18.0268. Accessed Jan 16, 2021
2.
Managing Healthcare Operations During COVID-19. Atlanta, Centers for Disease Control and Prevention, Feb 11, 2020. https://www.cdc.gov/coronavirus/2019-ncov/healthcare-facilities/guidance-hcf.html. Accessed April 3, 2020
3.
McGinty EE, Presskreischer R, Han H, et al: Psychological distress and loneliness reported by US adults in 2018 and April 2020. JAMA 2020; 324:93–94
4.
McKnight-Eily LR, Okoro CA, Strine TW, et al: Racial and ethnic disparities in the prevalence of stress and worry, mental health conditions, and increased substance use among adults during the COVID-19 pandemic—United States, April and May 2020. MMWR Morb Mortal Wkly Rep 2021; 70:162–166
5.
Overdose Deaths Accelerating During COVID-19. Atlanta, Centers for Disease Control and Prevention, Dec 21, 2020. https://www.cdc.gov/media/releases/2020/p1218-overdose-deaths-covid-19.html. Accessed Dec 30, 2020
6.
Auerbach J, Miller BF: COVID-19 exposes the cracks in our already fragile mental health system. Am J Public Health (Epub ahead of print, April 9, 2020)
7.
Golberstein E, Wen H, Miller BF: Coronavirus disease 2019 (COVID-19) and mental health for children and adolescents. JAMA Pediatr 2020; 174:819–820
8.
Pfefferbaum B, North CS: Mental health and the Covid-19 pandemic. N Engl J Med 2020; 383:510–512
9.
Panchal N, Kamal R, Orgera K, et al: The Implications of COVID-19 for Mental Health and Substance Use. Washington, DC, Kaiser Family Foundation, April 21, 2020. https://www.kff.org/health-reform/issue-brief/the-implications-of-covid-19-for-mental-health-and-substance-use. Accessed April 27, 2020
10.
Volkow ND: Collision of the COVID-19 and addiction epidemics. Ann Intern Med 2020; 173:61–62
11.
Alexander GC, Stoller KB, Haffajee RL, et al: An epidemic in the midst of a pandemic: opioid use disorder and COVID-19. Ann Intern Med 2020; 173:57–58
12.
Wakeman SE, Green TC, Rich J: An overdose surge will compound the COVID-19 pandemic if urgent action is not taken. Nat Med 2020; 26:819–820
13.
Öngür D, Perlis R, Goff D: Psychiatry and COVID-19. JAMA 2020; 324:1149–1150
14.
Hilty DM, Ferrer DC, Parish MB, et al: The effectiveness of telemental health: a 2013 review. Telemed J E Health 2013; 19:444–454
15.
Parish MB, Fazio S, Chan S, et al: Managing psychiatrist-patient relationships in the digital age: a summary review of the impact of technology-enabled care on clinical processes and rapport. Curr Psychiatry Rep 2017; 19:90
16.
Uscher-Pines L, Huskamp HA, Mehrotra A: Treating patients with opioid use disorder in their homes: an emerging treatment model. JAMA 2020; 324:39–40
17.
Lin LA, Fernandez AC, Bonar EE: Telehealth for substance-using populations in the age of coronavirus disease 2019: recommendations to enhance adoption. JAMA Psychiatry 2020; 77:1209–1210
18.
Uscher-Pines L, Sousa J, Raja P, et al: Suddenly becoming a “virtual doctor”: experiences of psychiatrists transitioning to telemedicine during the COVID-19 pandemic. Psychiatr Serv 2020; 71:1143–1150
19.
Yellowlees P, Nakagawa K, Pakyurek M, et al: Rapid conversion of an outpatient psychiatric clinic to a 100% virtual telepsychiatry clinic in response to COVID-19. Psychiatr Serv 2020; 71:749–752
20.
Uscher-Pines L, Sousa J, Raja P, et al: Treatment of opioid use disorder during COVID-19: experiences of clinicians transitioning to telemedicine. J Subst Abuse Treat 2020; 118:108124
21.
Wang L, Weiss J, Ryan EB, et al: Telemedicine increases access to buprenorphine initiation during the COVID-19 pandemic. J Subst Abuse Treat 2021; 124:108272
23.
Policy for Certain REMS Requirements During the COVID19 Public Health Emergency: Guidance for Industry and Health Care Professionals. Silver Spring, MD, US Food and Drug Administration, Center for Drug Evaluation and Research and Center for Biologics Evaluation and Research, 2020
24.
FAQs: Provision of Methadone and Buprenorphine for the Treatment of Opioid Use Disorder in the COVID-19 Emergency. Rockville, MD, Substance Abuse and Mental Health Services Administration, 2020. https://www.samhsa.gov/sites/default/files/faqs-for-oud-prescribing-and-dispensing.pdf
25.
Notification of Enforcement Discretion for Telehealth Remote Communications During the COVID-19 Nationwide Public Health Emergency. Washington, DC, US Department of Health and Human Services, March 17, 2020. https://www.hhs.gov/hipaa/for-professionals/special-topics/emergency-preparedness/notification-enforcement-discretion-telehealth/index.html. Accessed April 27, 2020
26.
Frequently Asked Questions: Behavioral Health Treatment Services Locator. Rockville, MD, Substance Abuse and Mental Health Services Administration, 2021. https://findtreatment.samhsa.gov/locator/faqs.html#.YBxxReiQE2w. Accessed Feb 4, 2021
27.
Behavioral Health Treatment Services Locator. Rockville, MD, Substance Abuse and Mental Health Services Administration, 2021. https://findtreatment.samhsa.gov. Accessed April 3, 2020
28.
Childs AW, Unger A, Li L: Rapid design and deployment of intensive outpatient, group-based psychiatric care using telehealth during coronavirus disease 2019 (COVID-19). J Am Med Inform Assoc 2020; 27:1420–1424
29.
Cummings JR, Allen L, Clennon J, et al: Geographic access to specialty mental health care across high- and low-income us communities. JAMA Psychiatry 2017; 74:476–484
30.
Cantor J, Stein BD, Saloner B: Telehealth capability among substance use disorder treatment facilities in counties with high versus low COVID-19 social distancing. J Addict Med 2020; 14:e366–e368
31.
Cantor JH, McBain RK, Kofner A, et al: Availability of outpatient telemental health services in the United States at the outset of the COVID-19 pandemic. Med Care 2021; 59:319–323
32.
Understanding the COVID-19 Pandemic. Washington, DC, USAFacts, 2021. https://usafacts.org/issues/coronavirus. Accessed July 25, 2020
33.
NCHS Urban-Rural Classification Scheme for Counties. Atlanta, Centers for Disease Control and Prevention, 2019. https://www.cdc.gov/nchs/data_access/urban_rural.htm. Accessed July 18, 2020
34.
About the American Community Survey. Washington, DC, US Census Bureau, 2021. https://www.census.gov/programs-surveys/acs/about.html. Accessed Jan 14, 2021
35.
Mapping Broadband Health in America. Washington, DC, Federal Communications Commission, 2016. https://www.fcc.gov/health/maps. Accessed Aug 4, 2020
36.
Austin PC, Hux JE: A brief note on overlapping confidence intervals. J Vasc Surg 2002; 36:194–195
37.
Stata Statistical Software: Release 16. College Station, TX, StataCorp LLC, 2019
38.
Canady VA: As MH workforce evolves during COVID-19, telehealth seen as new normal. Ment Health Wkly 2020; 30:1–4
39.
Lau J, Knudsen J, Jackson H, et al: Staying connected in the COVID-19 pandemic: telehealth at the largest safety-net system in the United States. Health Aff 2020; 39:1437–1442
40.
Uscher-Pines L: Moving on From Telehealth-By-Desperation: What Will Make Telehealth Stick? [blog]. Health Aff (Epub Aug 14, 2020). https://www.healthaffairs.org/do/10.1377/hblog20200810.737666/full. Accessed Nov 22, 2020
41.
Haque SN: Telehealth beyond COVID-19. Psychiatr Serv 2021; 72:100–103
42.
Trump Administration Finalizes Permanent Expansion of Medicare Telehealth Services and Improved Payment for Time Doctors Spend With Patients. Baltimore, Centers for Medicare and Medicaid Services, 2020. https://www.cms.gov/newsroom/press-releases/trump-administration-finalizes-permanent-expansion-medicare-telehealth-services-and-improved-payment. Accessed Feb 9, 2021
43.
Allen EM, Call KT, Beebe TJ, et al: Barriers to care and health care utilization among the publicly insured. Med Care 2017; 55:207–214
44.
Devoe JE, Baez A, Angier H, et al: Insurance + access not equal to health care: typology of barriers to health care access for low-income families. Ann Fam Med 2007; 5:511–518
45.
Lin C-CC, Dievler A, Robbins C, et al: Telehealth in health centers: key adoption factors, barriers, and opportunities. Health Aff 2018; 37:1967–1974
46.
Hudman J, McDermott D, Shanosky N: How Private Insurers Are Using Telehealth to Respond to the Pandemic. Washington, DC, Kaiser Family Foundation, 2020. https://www.kff.org/health-costs/issue-brief/how-private-insurers-are-using-telehealth-to-respond-to-the-pandemic. Accessed Feb 17, 2021
47.
Wood SM, White K, Peebles R, et al: Outcomes of a rapid adolescent telehealth scale-up during the COVID-19 pandemic. J Adolesc Health 2020; 67:172–178
48.
Silver Z, Coger M, Barr S, et al: Psychotherapy at a public hospital in the time of COVID-19: telehealth and implications for practice. Couns Psychol Q (Epub June 14, 2020)
49.
Basu S, Phillips RS, Phillips R, et al: Primary care practice finances in the United States amid the COVID-19 pandemic. Health Aff 2020; 39:1605–1614
50.
Keesara S, Jonas A, Schulman K: Covid-19 and health care’s digital revolution. N Engl J Med 2020; 382:e82
51.
Patrick SW, Richards MR, Dupont WD, et al: Association of pregnancy and insurance status with treatment access for opioid use disorder. JAMA Netw Open 2020; 3:e2013456
52.
Cantor J, McBain RK, Kofner A, et al: Fewer than half of us mental health treatment facilities provide services for children with autism spectrum disorder. Health Aff 2020; 39:968–974
53.
Beetham T, Saloner B, Wakeman SE, et al: Access to office-based buprenorphine treatment in areas with high rates of opioid-related mortality: an audit study. Ann Intern Med 2019; 171:1–9
54.
Beetham T, Saloner B, Gaye M, et al: Therapies offered at residential addiction treatment programs in the United States. JAMA 2020; 324:804–806
55.
Beetham T, Saloner B, Gaye M, et al: Admission practices and cost of care for opioid use disorder at residential addiction treatment programs in the US. Health Aff 2021; 40:317–325
56.
Vaughn SX, Maxey HL, Keen A, et al: Assessing public behavioral health services data: a mixed method analysis. Subst Abuse Treat Prev Policy 2020; 15:85

Information & Authors

Information

Published In

Go to Psychiatric Services
Go to Psychiatric Services
Psychiatric Services
Pages: 411 - 417
PubMed: 34407631

History

Received: 5 April 2021
Revision received: 4 June 2021
Accepted: 9 June 2021
Published online: 19 August 2021
Published in print: April 01, 2022

Keywords

  1. Coronavirus/COVID-19
  2. Drug abuse
  3. Mental health systems/hospitals
  4. Telehealth

Authors

Details

Jonathan Cantor, Ph.D. [email protected]
RAND Corporation, Santa Monica, California (Cantor, Hanson), Boston (McBain), Arlington, Virginia (Kofner), and Pittsburgh (Stein); Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston (Yu).
Ryan K. McBain, Ph.D., M.P.H.
RAND Corporation, Santa Monica, California (Cantor, Hanson), Boston (McBain), Arlington, Virginia (Kofner), and Pittsburgh (Stein); Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston (Yu).
Aaron Kofner, M.A.
RAND Corporation, Santa Monica, California (Cantor, Hanson), Boston (McBain), Arlington, Virginia (Kofner), and Pittsburgh (Stein); Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston (Yu).
Russell Hanson, B.S.
RAND Corporation, Santa Monica, California (Cantor, Hanson), Boston (McBain), Arlington, Virginia (Kofner), and Pittsburgh (Stein); Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston (Yu).
Bradley D. Stein, M.D., Ph.D.
RAND Corporation, Santa Monica, California (Cantor, Hanson), Boston (McBain), Arlington, Virginia (Kofner), and Pittsburgh (Stein); Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston (Yu).
Hao Yu, Ph.D.
RAND Corporation, Santa Monica, California (Cantor, Hanson), Boston (McBain), Arlington, Virginia (Kofner), and Pittsburgh (Stein); Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston (Yu).

Notes

Send correspondence to Dr. Cantor ([email protected]).

Competing Interests

The authors report no financial relationships with commercial interests.

Funding Information

Support was provided by grant R01MH112760 from the National Institute of Mental Health.

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

View Options

View options

PDF/EPUB

View PDF/EPUB

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login
Purchase Options

Purchase this article to access the full text.

PPV Articles - Psychiatric Services

PPV Articles - Psychiatric Services

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share